Last updated on May 2019

A phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, 52-week efficacy and safety study of RO5285119 in adults with autism spectrum disorders (ASD) with a 2-year open label extension


Brief description of study

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, 52-WEEK EFFICACY AND SAFETY STUDY OF RO5285119 IN ADULTS WITH AUTISM SPECTRUM DISORDERS (ASD) WITH A 2-YEAR OPEN LABEL EXTENSION

 

Detailed Study Description

Adult Autism disorder trial with an open label extension

 

Clinical Study Identifier: TX151026

Find a site near you

Start Over

Northwest Clinical Research Center

1951 152nd Pl NE Suite 200 Bellevue, WA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.